聯邦制藥(03933.HK)年度純利減少6%至6.42億元 末期息7分
格隆匯3月31日丨聯邦制藥(03933.HK)公佈，截至2019年12月31日止年度，公司收入83.93億元人民幣，同比增長11.7%；除税前溢利8.42億元，同比增長6%；公司擁有人應占溢利6.42億元，同比減少6%；每股盈利39.14分，末期股息每股人民幣7分。
集團製劑產品取得分部營業額人民幣35.19億元，同比增長21.9%。其中，胰島素系列持續為製劑產品業務增長提供動力，於年內合計錄銷售收入約人民幣9億元，較2018年增長約30%。重組胰島素注射液及甘精胰島素注射液銷售數量同比分別增長12.7%及158.5%。
集團其他製劑產品保持穩定增長。其中，注射用呱拉西林鈉他唑巴坦鈉年內銷售收入同比增長44.0%，位列製劑產品單品銷售冠軍；阿莫西林膠囊銷售收入同比增長17.8%。此外，治療中重度阿爾茨海默型痴呆的鹽酸美金剛系列增長理想，年內銷售收入同比增長77.3%。
集團持續致力藥品研發，現時開發中的新產品達29種，有望進一步擴大製劑產品儲備。其中，門冬胰島素注射液及門冬胰島素30注射液目前處於生產申報階段；利拉魯肽注射液已進入臨牀試驗階段；德谷胰島素注射液已於2019年9月獲批臨牀試驗。基於日趨完善的生物研發平台，集團將繼續拓展於內分泌及自身免疫疾病等領域的相關產品佈局。化藥產品研發方面，集團重點佈局在乙肝、眼科用藥等產品，並將繼續向新藥領域拓展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
